Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Samaritan Pharmaceuticals has entered into a licensing agreement with CHDI Foundation, a nonprofit organization pursuing the discovery and development of drugs to delay or slow the progression of Huntington's disease.
Subscribe to our email newsletter
Under the terms of the agreement, Samaritan will grant CHDI an 18-month non-exclusive license to evaluate the usefulness of six of Samaritan’s Alzheimer’s drugs, SP-233, Sp-sc4, Sp-sc7, Sp-04, Sp-04m, and Sp-08, as possible therapeutics for Huntington’s disease (HD). CHDI will pay for the cost of this evaluation and Samaritan will retain all rights in its compounds.
Janet Greeson, CEO of Samaritan, said: “We believe our central nervous system (CNS) drugs hold a lot of promise to cognitively improve Alzheimer’s patients and protect their brain from further damage, so we are extremely hopeful our drugs will demonstrate and hold the same promise for Huntington’s disease.”